Biotest
Biotest AG, a leading player in the biopharmaceutical industry, is headquartered in Dreieich, Germany. Founded in 1946, the company has established itself as a pioneer in the development and production of immunoglobulins and blood plasma products. With a strong focus on therapeutic areas such as immunology and haematology, Biotest is committed to enhancing patient care through innovative solutions.
The company’s core offerings include high-quality plasma-derived therapies, which are distinguished by their rigorous quality standards and advanced manufacturing processes. Biotest has achieved significant milestones, including the expansion of its global presence, with operations spanning Europe, North America, and Asia. Renowned for its commitment to research and development, Biotest continues to solidify its market position as a trusted provider of essential biopharmaceuticals, contributing to improved health outcomes worldwide.
+5 vs industry average
Biotest’s score of 43 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Biotest?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Biotest's reported carbon emissions
In 2024, Biotest's total carbon emissions amounted to approximately 92,215,000 kg CO2e, with emissions distributed across Scope 2 and Scope 3. Specifically, Scope 2 emissions were about 12,430,900 kg CO2e, while Scope 3 emissions totalled approximately 92,215,000 kg CO2e. Notably, the company does not report Scope 1 emissions data. In 2023, Biotest reported total emissions of approximately 102,043,000 kg CO2e, with Scope 2 emissions at about 11,457,000 kg CO2e and Scope 3 emissions reaching approximately 102,043,000 kg CO2e. Biotest has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The company is a current subsidiary of Biotest Aktiengesellschaft, which may influence its emissions reporting and climate commitments. Overall, Biotest's emissions data reflects a significant reliance on Scope 3 emissions, highlighting the importance of addressing upstream and downstream activities in their climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Biotest’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Biotest yet.
Scope 3 top emissions categories
4 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Inherited from Grifols, S.A.
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Biotest
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project